These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 18622408)
1. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Capasso R; Borrelli F; Cascio MG; Aviello G; Huben K; Zjawiony JK; Marini P; Romano B; Di Marzo V; Capasso F; Izzo AA Br J Pharmacol; 2008 Nov; 155(5):681-9. PubMed ID: 18622408 [TBL] [Abstract][Full Text] [Related]
2. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice. Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335 [TBL] [Abstract][Full Text] [Related]
3. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370 [TBL] [Abstract][Full Text] [Related]
4. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680 [TBL] [Abstract][Full Text] [Related]
5. Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo. Aviello G; Borrelli F; Guida F; Romano B; Lewellyn K; De Chiaro M; Luongo L; Zjawiony JK; Maione S; Izzo AA; Capasso R J Mol Med (Berl); 2011 Sep; 89(9):891-902. PubMed ID: 21499737 [TBL] [Abstract][Full Text] [Related]
6. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Capasso R; Borrelli F; Aviello G; Romano B; Scalisi C; Capasso F; Izzo AA Br J Pharmacol; 2008 Jul; 154(5):1001-8. PubMed ID: 18469842 [TBL] [Abstract][Full Text] [Related]
7. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Fichna J; Dicay M; Lewellyn K; Janecka A; Zjawiony JK; MacNaughton WK; Storr MA Inflamm Bowel Dis; 2012 Jun; 18(6):1137-45. PubMed ID: 21953882 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Izzo AA; Capasso R; Aviello G; Borrelli F; Romano B; Piscitelli F; Gallo L; Capasso F; Orlando P; Di Marzo V Br J Pharmacol; 2012 Jun; 166(4):1444-60. PubMed ID: 22300105 [TBL] [Abstract][Full Text] [Related]
9. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Fichna J; Schicho R; Andrews CN; Bashashati M; Klompus M; McKay DM; Sharkey KA; Zjawiony JK; Janecka A; Storr MA Neurogastroenterol Motil; 2009 Dec; 21(12):1326-e128. PubMed ID: 19650775 [TBL] [Abstract][Full Text] [Related]
10. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220 [TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Izzo AA; Fezza F; Capasso R; Bisogno T; Pinto L; Iuvone T; Esposito G; Mascolo N; Di Marzo V; Capasso F Br J Pharmacol; 2001 Oct; 134(3):563-70. PubMed ID: 11588110 [TBL] [Abstract][Full Text] [Related]
12. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics. Cruz A; Domingos S; Gallardo E; Martinho A Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678 [TBL] [Abstract][Full Text] [Related]
13. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Lee DY; Ma Z; Liu-Chen LY; Wang Y; Chen Y; Carlezon WA; Cohen B Bioorg Med Chem; 2005 Oct; 13(19):5635-9. PubMed ID: 16084728 [TBL] [Abstract][Full Text] [Related]
14. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611 [TBL] [Abstract][Full Text] [Related]
15. Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands. Polepally PR; White K; Vardy E; Roth BL; Ferreira D; Zjawiony JK Bioorg Med Chem Lett; 2013 May; 23(10):2860-2. PubMed ID: 23587424 [TBL] [Abstract][Full Text] [Related]
16. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Capasso R; Borrelli F; Capasso F; Siebert DJ; Stewart DJ; Zjawiony JK; Izzo AA Neurogastroenterol Motil; 2006 Jan; 18(1):69-75. PubMed ID: 16371085 [TBL] [Abstract][Full Text] [Related]
17. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673 [TBL] [Abstract][Full Text] [Related]
18. Chemical syntheses of the salvinorin chemotype of KOR agonist. Hill SJ; Brion AUCM; Shenvi RA Nat Prod Rep; 2020 Nov; 37(11):1478-1496. PubMed ID: 32808003 [TBL] [Abstract][Full Text] [Related]
20. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]